Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9997709 | PMC |
| http://dx.doi.org/10.3389/fonc.2023.1141161 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ovarian tumor microenvironment contributes to tumor progression and chemoresistance.
Cancer Drug Resist
December 2024
Precision Health Program, Michigan State University, East Lansing, MI 48824, USA.
Ovarian cancer is one of the deadliest gynecologic cancers affecting the female reproductive tract. This is largely attributed to frequent recurrence and development of resistance to the platinum-based drugs cisplatin and carboplatin. One of the major contributing factors to increased cancer progression and resistance to chemotherapy is the tumor microenvironment (TME).
View Article and Find Full Text PDFOvercoming drug resistance through extracellular vesicle-based drug delivery system in cancer treatment.
Cancer Drug Resist
December 2024
Tianjin Key Laboratory of Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmaceutical Sciences; Tianjin Medical University, Tianjin 300070, China.
Drug resistance is a major challenge in cancer therapy that often leads to treatment failure and disease relapse. Despite advancements in chemotherapeutic agents and targeted therapies, cancers often develop drug resistance, making these treatments ineffective. Extracellular vesicles (EVs) have gained attention for their potential applications in drug delivery because of their natural origin, biocompatibility, and ability to cross biological barriers.
View Article and Find Full Text PDFSafety in Subsequent Lines of Therapy in Patients With Relapsed/Refractory Follicular Lymphoma.
J Adv Pract Oncol
November 2024
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.
Follicular lymphoma (FL) is a disease often characterized by chronic and successive relapses after first-line chemoimmunotherapy. Although chemoimmunotherapy and combination therapy, such as lenalidomide with rituximab, are well established in the treatment sequence of FL, there is a need to streamline treatment options and determine placement of novel agents, such as chimeric antigen receptor T-cell therapy, an enhancer of zeste homolog 2 inhibitor, or a phosphoinositide 3 kinase inhibitor, into the treatment landscape. As such, the purpose of this review is to compare the safety profiles of approved agents in subsequent lines of therapy for relapsed or refractory FL and to assess how the management of adverse events may impact treatment choice.
View Article and Find Full Text PDFThe Development and Appraisal of MELD 3.0 in Liver Diseases: Good Things Never Come Easy.
J Clin Transl Hepatol
January 2025
Department of Gastroenterology and Hepatology, Tianjin Medical University General Hospital, Tianjin, China.
Since its proposal, the Model for End-Stage Liver Disease (MELD) score has been employed to predict short-term mortality among patients with chronic liver disease and those awaiting liver transplantation, serving as the primary criterion for organ allocation. However, as the demographic and epidemiological characteristics of chronic liver disease and liver transplantation have evolved, a range of MELD-related scores has emerged, including MELD-Na, iMELD, delta MELD, MELD XI, MELD-LA, and pediatric end-stage liver disease, culminating in the recently proposed MELD 3.0, which builds upon MELD-Na.
View Article and Find Full Text PDFMinimally Invasive Surgery Deserts: Is There a Role for Robotic Assisted Surgery?
JSLS
January 2025
Department of Surgery, Mayo Clinic Arizona, Phoenix, AZ. (Dr. Fong).
Despite evidence indicating patient and hospital benefits of minimally invasive surgery (MIS) over open surgery, there is still access barriers to MIS. Availability of training and associated learning curve, health literacy, and hospital characteristics (location, size) have been identified as the primary barriers to the adoption of MIS. Robotic assisted surgery could help to overcome some of these barriers and increase access to MIS through easier tele-mentoring and potential for remote access.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!